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Background:  Chronic kidney disease (CKD) is an evolving paradigm for cardiovascular risk assessment: however, its association with peripheral 
arterial disease (PAD) has not been fully elucidated in Japanese population. We investigated whether low levels of estimated glomerular filtration 
rate (eGFR) can predict the comorbidity of PAD.
Methods:  This retrospective study comprised serial 603 hospitalized patients (mean 68.0±12.9 years old, 426 men), including patients with 
ischemic heart disease (55.2%) and patients with stage 3-5 CKD: eGFR< 60ml/min/1.73m2 (35.2%). PAD was determined by the ankle-brachial 
pressure index (ABI) <0.9, and observed in 70 patients (11.6%).
Results:  ABI levels were significantly lower in patients with stage 3-5 CKD compared with those with CKD≤2 (1.02±0.19 vs 1.11±0.15, p<0.001). 
Univariate analyses revealed that the presence of PAD was associated with age, males, systolic BP, diabetes, dialysis, and with CKD stage 
classification (OR 2.098, 95%CI 1.625-2.709, p<0.001). Multivariate logistic regression analyses with adjustment for covariates (age, male, systolic 
BP, and HbA1c) revealed that the presence of PAD was independently predicted by the CKD classification (OR 2.055, 95% CI 1.547-2.730, p<0.001).
Conclusions: The low levels of eGFR, especially equivalent to stage 3-5 CKD, could be an independent and significant predictor for the comorbidity 
of PAD. Targeted screening with ABI should be beneficial for patients with low eGFR levels.
